Clinical Trials Logo
  1. Home
  2. Primary Myelofibrosis (PMF)
  3. NCT01558739

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) — MACS2030  

Primary Myelofibrosis (PMF) Clinical Trial

Official title:
A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy of INC424 in patients with PMF, PPV MF, or PET-MF using a composite measure of either an objective endpoint (> 50% reduction in splenomegaly using palpitation at 48 weeks) and/or a subjective endpoint (>50% reduction in total symptom score at 48 weeks).

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01558739
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 4
Start date May 2012
Completion date January 2014
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03441113 - Extended Access of Momelotinib in Adults With Myelofibrosis Phase 2
Completed NCT00910728 - Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases Phase 1
Completed NCT02101268 - Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Phase 3
Completed NCT03136185 - Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Phase 1/Phase 2
Completed NCT04217993 - Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis Phase 2
Completed NCT02515630 - Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Phase 2
Recruiting NCT03662126 - KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment Phase 2/Phase 3
Terminated NCT03935555 - Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib Phase 1
Recruiting NCT04878003 - Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis Phase 2
Available NCT04745637 - Managed Access Programs for INC424, Ruxolitinib